May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Evaluation of Early Sclerochoroidal Abnormalities in Hypercholesterolemic Rabbits Submitted to the PPAR-Gamma Agonist Treatment (Rosiglitazone): Histological and Histomorphometric Study
Author Affiliations & Notes
  • R. J. Torres
    Retina Vitreous Department, UNIFESP, Curitiba, Brazil
  • M. Maia, II
    Retina Vitreous Department, Cardiology,
    UNIFESP, Sao Paulo, Brazil
  • D. Precoma
    Retina Vitreous Department, Cardiology,
    Pontificia Universidade Catolica do Parana, Curitiba, Brazil
  • M. Farah
    Retina Vitreous Department, Cardiology,
    UNIFESP, Sao Paulo, Brazil
  • L. Noronha
    Uveitis, Pathology,
    Pontificia Universidade Catolica do Parana, Curitiba, Brazil
  • A. Luchini
    Centro Oftalmologico de Curitiba, Curitiba, Brazil
  • D. Brick
    Retina Vitreous Department, Hospital Angelina Caron, Curitiba, Brazil
  • C. Muciolli
    Uveitis, Pathology,
    UNIFESP, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships  R.J. Torres, None; M. Maia, None; D. Precoma, None; M. Farah, None; L. Noronha, None; A. Luchini, None; D. Brick, None; C. Muciolli, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1376. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. J. Torres, M. Maia, II, D. Precoma, M. Farah, L. Noronha, A. Luchini, D. Brick, C. Muciolli; Evaluation of Early Sclerochoroidal Abnormalities in Hypercholesterolemic Rabbits Submitted to the PPAR-Gamma Agonist Treatment (Rosiglitazone): Histological and Histomorphometric Study. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1376. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate, in a rabbit model, the degenerative histological abnormalities in the choroids and sclera following the daily administration of high cholesterol dosages as well as the possible prevention of degenerative abnormalities following systemic administration of oral rosiglitazone, an activator of agonist PPAR ocular gamma receptors.

Methods: : 55 New Zealand rabbits were studied and divided into four groups: Control Group (CG) (06 rabbits): normal diet for 6 weeks; Second group (G1) (13 rabbits): 1% cholesterol diet for 2 weeks and then a 0.5%cholesterol diet for 4 weeks. Third group (G2) (18 rabbits):1% cholesterol diet for 2 weeks and then a 0.5% cholesterol diet for 4 weeks; this group also received 3 mg of rosiglitazone daily after the third week from the beginning of the experiment. Fourth group (G3) (18 rabbits):1%cholesterol diet for 2 weeks and then a 0.5% cholesterol diet for 4 weeks; this group also received 3 mg rosiglitazone since the beginning of the experiments. Data was analyzed by Shapiro-Wilks-Test and P values lower than 0.05 were considered statistically significant.

Results: : No abnormalities were observed in CG. However, G1 group showed a significant increase in sclerochoroidal thickness (301,48 micrometers-mc±50,12) compared with CG (239,09mc±24,33)(p=0,005).The G2 group showed a lower sclerochoroidal thickness (282,08mc±36,44) than G1 (301,48mc±50,12); however, this value was not statistically significant (p=0,222). G3 group showed a lower sclerochoroidal thickness (266,11mc±47,94 ) than G1 (301,48mc±50,12); this value was statistically significant (p=0,02). A higher number of histiocytes was observed in the scleral wall of G1 group.

Conclusions: : This study revealed that hypercholesterolemia may lead to early degenerative abnormalities of the choroids and sclera of rabbits and that the activation of agonist PPAR ocular gamma receptors, by means of oral administration of rosiglitazone, proved to be effective for the preservation of choroids and sclera anatomy. These findings may have clinical relevance as the rosiglitazones may offer a new treatment modality for dry and/or exsudative AMD in human eyes.

Keywords: age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×